Synergy Pharmaceuticals, Inc. (SGYP) Shares Bought by Metropolitan Life Insurance Co. NY

Metropolitan Life Insurance Co. NY boosted its position in shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) by 5.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 134,855 shares of the biopharmaceutical company’s stock after buying an additional 7,195 shares during the period. Metropolitan Life Insurance Co. NY owned 0.06% of Synergy Pharmaceuticals worth $628,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in SGYP. Teachers Advisors LLC raised its stake in shares of Synergy Pharmaceuticals by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares of the biopharmaceutical company’s stock worth $1,820,000 after buying an additional 11,521 shares in the last quarter. Nationwide Fund Advisors raised its position in Synergy Pharmaceuticals by 9.1% in the first quarter. Nationwide Fund Advisors now owns 301,829 shares of the biopharmaceutical company’s stock worth $1,407,000 after buying an additional 25,113 shares during the last quarter. Clear Harbor Asset Management LLC raised its position in Synergy Pharmaceuticals by 32.5% in the first quarter. Clear Harbor Asset Management LLC now owns 295,060 shares of the biopharmaceutical company’s stock worth $1,375,000 after buying an additional 72,300 shares during the last quarter. Janney Montgomery Scott LLC raised its position in Synergy Pharmaceuticals by 27.4% in the first quarter. Janney Montgomery Scott LLC now owns 30,200 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 6,500 shares during the last quarter. Finally, Hikari Power Ltd acquired a new position in Synergy Pharmaceuticals during the first quarter worth $699,000. 67.56% of the stock is currently owned by institutional investors and hedge funds.

Synergy Pharmaceuticals, Inc. (NASDAQ SGYP) traded up 2.76% on Friday, hitting $2.98. The stock had a trading volume of 1,890,173 shares. Synergy Pharmaceuticals, Inc. has a 1-year low of $2.85 and a 1-year high of $7.15. The stock has a 50 day moving average price of $3.97 and a 200 day moving average price of $4.54. The company’s market cap is $670.36 million.

Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.08. The firm had revenue of $2.31 million during the quarter, compared to analysts’ expectations of $1.98 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. On average, equities research analysts expect that Synergy Pharmaceuticals, Inc. will post ($1.09) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/08/18/metropolitan-life-insurance-co-ny-has-628000-position-in-synergy-pharmaceuticals-inc-sgyp-updated.html.

A number of research analysts recently weighed in on the company. BTIG Research reissued a “buy” rating and set a $11.00 target price on shares of Synergy Pharmaceuticals in a report on Tuesday, June 27th. BidaskClub upgraded Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Zacks Investment Research upgraded Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Canaccord Genuity reiterated a “buy” rating and set a $13.00 target price on shares of Synergy Pharmaceuticals in a research report on Monday, July 10th. Finally, Citigroup Inc. reissued a “sell” rating and issued a $3.70 price target on shares of Synergy Pharmaceuticals in a research note on Wednesday, June 28th. Four investment analysts have rated the stock with a sell rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $10.07.

In other news, major shareholder Paulson & Co. Inc. sold 26,287 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $3.77, for a total value of $99,101.99. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 3.80% of the company’s stock.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

What are top analysts saying about Synergy Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Synergy Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit